We report here that targeted chemogenetic activation of the PB complex produces sustained EEG and behavioral arousal in the rat. We further establish, using viral-mediated retrograde activation, that PB projections to the preoptic-basal forebrain and lateral hypothalamus, but not to the thalamus, mediate PB-driven wakefulness. We exploited this novel and noninvasive model of induced wakefulness to explore the EEG and metabolic consequences of extended wakefulness. Repeated (daily) chemogenetic activation of the PB was highly effective in extending wakefulness over 4 days, although subsequent PB activation produced progressively lesser wake amounts. Curiously, no EEG or behavioral sleep rebound was observed, even after 4 days of induced wakefulness. Following the last of the four daily induced wake bouts, we examined the brains and observed a chimeric pattern of c-Fos expression, with c-Fos expressed in subsets of both arousal-and sleep-promoting nuclei. From a metabolic standpoint, induced extended wakefulness significantly reduced body weight and leptin but was without significant effect on cholesterol, triglyceride, or insulin levels, suggesting that high sleep pressure or sleep debt per se does not, as previously implicated, result in a deleterious metabolic phenotype.
In Brief
Qiu et al. show that targeted activation of the pontine parabrachial nucleus potently drives-via the basal forebrain and lateral hypothalamus, but not thalamuscortical arousal and behavioral wake. They also demonstrate that repeated activation of the PB reliably extends wakefulness without sleep rebound or deleterious metabolic changes.
INTRODUCTION
The parabrachial complex (PB) of the dorsolateral pons provides extensive, largely glutamatergic, ascending innervation of the cerebral cortex, basal forebrain (BF), hypothalamus, thalamus, amygdala complex, and descending projections to medullary regions [1] [2] [3] [4] . Together, these projections enable the PB to exert powerful control over a wide range of neurobiological functions, including thermoregulation, respiration, pain, fear, and feeding [5] [6] [7] . Inputs to the PB complex include most of its own targets as well as the spinal cord [2, 8, 9] . In its most fundamental neurobiological context, however, the PB plays an indispensable role in generating and maintaining electroencephalogram (EEG) arousal and behavioral wakefulness [10] . For example, cell-body-specific lesions of the medial PB (MPB) and lateral PB (LPB) in rats results in $40% and $10% reduction in wakefulness, respectively, whereas lesions encompassing the entire PB complex produce a coma-like state, i.e., a monotonous <1.0-Hz EEG and behavioral unresponsiveness. Genetically driven disruption of glutamate transmission by PB neurons also results in a large reduction in total wake and slowing of the waking EEG [11] . Thus, whereas lesions of the PB can dramatically reduce EEG and behavioral arousal, it remains unknown whether acute activation of the PB is sufficient to trigger and maintain EEG and behavioral arousal.
The circuit basis through which the PB might drive EEG and behavioral arousal also remains unclear. On the basis of our previous finding that lesions of both cholinergic and non-cholinergic corticopetal BF neurons result in coma [10] , we proposed a PB-BF-cortex pathway as the structural basis by which the PB maintains EEG and behavioral arousal. It is the case, however, that the preoptic area (POA) hypothalamus, lateral hypothalamus (LH), and thalamus may also mediate PB control of wakefulness, as these forebrain structures are also densely innervated by the PB and, for the most part, provide direct innervation of the cortex [12] . To evaluate the role of these respective PB afferent pathways in arousal, we employed, in combination, a viral-based retrograde and excitatory chemogenetic system to selectively activate the PB-POA-BF, PB-LH, and PB-thalamus pathways.
We finally asked whether chronic activation of the PB might provide a novel and noninvasive (i.e., absence of external stressor) way to extend wakefulness, as this would facilitate the assessment of the EEG and metabolic consequences of extended wakefulness per se. To this end, extended wakefulness in humans, by means of sleep restriction or deprivation, produced deleterious metabolic changes [13] [14] [15] [16] , whereas animal studies have provided mixed results [17, 18] .
RESULTS

Chemogenetic Stimulation of the PB Induces a Long Wakefulness
To examine the effect of PB activation on EEG and behavioral wakefulness, we placed bilateral injections of an adeno-associated viral (AAV) vector containing an excitatory modified muscarinic G-protein-coupled receptor (AAV 10 -Ef1a-hM3Dq-mCherry; hereafter, AAV-hM3Dq) into the PB of seven rats ( Figure 1A ) along with EEG/electromyogram (EMG) electrodes. Histolog- Figure 1E illustrates the timeline of procedures on animals.
Three weeks after surgery, we administered vehicle (i.p.; saline) at 9 a.m. and, 1 day later, CNO (i.p.; 0.2 mg/kg), also at 9 a.m., to the AAV-hM3Dq rats. The animals were housed under a 12:12 light-dark (LD), with L on at 7 a.m. As compared to saline injections, CNO injection at 9 a.m. in the rats produced $11 hr of continuous wakefulness (Figures 2A  and 2B , black, and Figure 2C , the redcolored hourly time course of wakefulness). As compared with spontaneous wakefulness (Figure 2A, a) , the rats remained relatively behaviorally quiet but with increased EEG power in the 5.0-Hz theta band (Figures 2Bb and 2E , upper left) during CNO-induced wakefulness. We analyzed the fast Fourier transform (FFT) spectra of each behavioral state (wake, non-rapid eye movement [NREM] , and rapid eye movement (legend continued on next page) CNO injection, the average FFT of NREM sleep was reduced in the 0-to 3-Hz (delta) and 7-to 8-Hz (theta; Figure 2E , middle left) frequency ranges; no significant change was seen in the FFT of REM sleep ( Figure 2E , bottom left). During the subsequent 9 p.m.-7 a.m. period, the reduced low-frequency power of NREM sleep (0-5.5 Hz) was still present ( Figure 2E , middle right), the FFT of wake did not completely return to the pattern resembling baseline ( Figure 2E , top right), and the REM sleep FFT was virtually identical to the baseline level ( Figure 2E , bottom right). Despite the prolonged wakefulness, no EEG or behavioral sleep rebound (i.e., increased low-frequency power in the FFT of NREM sleep or increased behavioral sleep; Figures 2C-2E) was observed during the night following the arousal effects of CNO. These results indicate that activation of hM3Dq+ PB neurons by CNO has a long-lasting effect on behavior arousal and an even longer effect on the EEG, in particular during NREM sleep.
One week after the behavioral experiments, and so that we could examine the pattern of post-CNO neuronal activity, we again injected animals with CNO at 9 a.m. but this time perfused 
Chemogenetic Stimulation of PB-BF-POA Pathway Promotes Wake Behavior
We next sought to define the circuit basis by which the PB might drive EEG and behavioral arousal. To this end, we have previously shown that, in the rat, the PB-BF-cortex route is critical for cortical arousal [10] . Here, we asked whether the PB might regulate the absolute time of waking via the BF exclusively or perhaps also via the hypothalamus and/or thalamus. Within the hypothalamus, both the POA and LH are involved in sleepwake regulation and the PB innervates both regions. To first ascertain the relative contribution of the PB-POA pathway to the wake-promoting effects of PB activation, we placed bilateral injection of a retrograde viral vector (AAV 6 -cre, which is taken up by the axonal terminals and retrogradely transported to the neuronal bodies) [19, 20] into the POA-including the MnPO and VLPO-as well as bilateral injections of cre-dependent AAV-hM3Dq into the PB of seven rats. In other words, this approach enabled us to selectively express the hM3Dq receptors in PB neurons that project to the BF and POA. Three weeks post-injection, EEG/EMG and video were recorded in all animals. Rats received saline injections at 9 a.m. and CNO injections at 9 a.m. the next day. A week later, rats were perfused at 11 a.m. after CNO injection at 9 a.m.
The AAV 6 -cre injections were verified by cre immunostaining, which in the case of the POA injections invariably included some of the magnocellular BF, in addition to the entire POA ( Figure 4A) ; expression of hM3Dq receptors in PB neurons was verified by directly visualizing the fusion reporter mCherry (red color) under the fluorescent microscope ( Figures 4B-4E ). During the period 9 a.m.-1 p.m., activation of the PB-preoptic pathway by CNO injection significantly increased wakefulness (Figures 5A and 5B) and decreased the EEG power density of NREM sleep in the frequency range of 1-2.5 Hz during the first 4 hr after CNO administration ( Figure 5C , left panel). EEG power density of wakefulness and REM sleep were not different from saline-injected control levels ( Figure 5C , left panel). There was a trend of behavioral sleep rebound during 3 p.m.-6 p.m., but it did not reach statistical significance ( Figure 5A ). However, the NREM EEG power in the 2-to 4-Hz range was elevated during this period ( Figure 5C , right panel), suggesting some EEG sleep rebound.
Chemogenetic Stimulation of the PB-LH Pathway Promotes Wake Behavior
We next sought to determine whether selective activation of the PB-LH pathway would also promote wakefulness. To do so, we injected AAV 6 -cre into the pLH and AAV-hM3Dq into the PB of six rats. Cre immunostaining and the fluorescent reporter mCherry shown in Figures 4F-4J verified the AAV 6 -cre injection sites in pLH ( Figure 4F ) and the hM3Dq expression in the PB (Figures 4G-4J) . Activation of the PB-LH pathway by CNO significantly increased wakefulness ( Figures 5D and 5E ), reduced delta power, and increased power in the 6-to 7-Hz frequency range of NREM sleep during the 4-hr post-injection window, as Values are means ± SEM. *p < 0.05; **p < 0.01. 3V, third ventricle; 4V, fourth ventricle; 7n, facial nerve; ac, anterior commissure; cc, corpus callosum; ChAT, choline acetyltransferase; CM, central medial thalamic nucleus; f, fornix; fr, fasciculus retroflexus; GP, globus pallidus; ic, internal capsule; LC, locus coeruleus; LH, lateral hypothalamus; LV, lateral ventricle; MnPO, median preoptic nucleus; mt, mammillothalamic tract; och, optic chiasm; PSTh, parasubthalamic nucleus; PVP, paraventricular thalamic nucleus, Post; PZ, parafacial zone; scp, superior cerebellar peduncle; stria, striatum; TMN, tuberomammillary nucleus; VLPO, ventrolateral preoptic nucleus. compared with the EEG following saline injections ( Figure 5F , left panel). The EEG power density of wakefulness and REM sleep were not altered ( Figure 5F , left panel). Behavioral sleep rebound was observed during the night period but was not accompanied by EEG rebound (Figures 5D-5F , right panel).
Chemogenetic Activation of PB-Thalamic Pathway Does Not Affect Wake Behavior Another major target of the PB is the midline and intralaminar thalamus, a subcortical structure long implicated in EEG and behavioral arousal [21] [22] [23] . To determine whether selective activation of the PB-thalamic pathway promotes wakefulness, we injected AAV 6 -cre into the midline and intralaminar thalamus and cre-dependent AAV-hM3Dq into the PB of six rats. Figures  4K-4O show the AAV 6 -cre injection sites in the thalamus and the hM3Dq expression within the PB. In sharp contrast to that seen following activation of the PB-BF-POA and PB-LH pathways, activation of the PB-thalamic pathway produced only a transient increase in wake ( Figures 5G and 5H ) and was without effect on EEG FFT during wake, NREM, or REM sleep ( Figure 5I ).
Effects of Extended Wakefulness on EEG and Behavioral
Sleep-Wake and Underlying Sleep-Wake Circuitry To examine the effects of extended wakefulness, i.e., presumptive high sleep pressure, on sleep-wake states, sleep rebound, and the EEG power spectra, we injected CNO at 9 a.m. for 4 consecutive days in seven rats and continuously recorded EEG/EMG. Four hours after the fourth CNO injection (9 a.m.), the rats were perfused (1 p.m.). With respect to the duration of wakefulness induced by CNO, we found that the induced wakefulness was progressively reduced from $11 hr on the 1 st day to 7 hr on the 2 nd day and to 5 hr on the 3 rd day ( Figure 2C ). It is of interest, however, that, in spite of the reduction in the magnitude of wake induction, no EEG or behavioral sleep rebound was observed on any of the days following dissipation of the CNO effect ( Figures 2C and 2D, middle) .
Similar to that observed following the initial injection of CNO, wake and NREM sleep FFT was altered following the second CNO injection, and again, the EEG effects persisted beyond that seen on waking behavior ( Figure 6A ). By the third CNO injection, the wake FFT was gradually reduced but never returned to normal baseline wake FFT patterns ( Figure 6A, upper panel) . NREM sleep FFT remained altered by the third and fourth CNO injection ( Figure 6A , middle panel), whereas the REM sleep FFT remained unaltered by repeated CNO injections ( Figure 6A , lower panel).
To examine the persistence of CNO effects on the EEG, we analyzed the averaged FFT of each stage during the period from 7 to 9 a.m., which were the 2 hr prior to each CNO injection. Wake FFT during the 7-9 a.m. period, and so nearly a full day after the first and second CNO injections, continued to exhibit differences from the baseline FFT of the same period, whereas no differences between the wake FFT during the last 7-9 a.m. period and baseline ( Figure 6B , upper panel) were observed, indicating that the waking EEG returned to baseline spectrum following the third CNO injection. On the other hand, the NREM sleep FFT continued to show lower delta power than the baseline level ( Figure 6B , middle panel) 24 hr after the first, second, and third CNO injections. REM sleep FFT was not altered during any of the 7-9 a.m. post-CNO injection times. These results indicate that PB activation by CNO has a muchlonger-lasting effect on the EEG activity than its effects on behavior and that sleep pressure progressively reduces the behavioral waking and FFT effects of CNO.
c-Fos expression in sleep-wake circuits after the fourth CNO injection was also markedly different from that observed following the first CNO injection. Figure 3C , ii), and PB (Figure 6C ) was much higher than that observed in the typical sleep condition, resembling instead that of a normal spontaneous wake c-Fos pattern.
Effects of Extended Wakefulness on Body Weight and Energy Metabolism
We finally examined the effects of extended wakefulness, and hence sleep loss, over 4 consecutive days on body weight and metabolic biomarkers. As compared with controls, the CNO-injected rats experienced a cumulative sleep loss of about 27 hr across the 4 days. Compared with controls, we found a significant reduction in body weight (baseline: 338.8 ± 6.5 g; CNO 3 4: 318.5 ± 5.1 g; p = 0.039) and leptin (control: 2.4 ± 0.4 ng/ml; CNO 3 4: 1.1 ± 0.2 ng/ml; p = 0.013) following the extended CNO-induced wakefulness. On the other hand, blood glucose (control: 148.7 ± 19.3 mg/dl; CNO 3 4: 204.5 ± 9.1 mg/dl; p = 0.035) was increased ( Figures 7A and 7B) , whereas insulin levels were unchanged ( Figure 7B) , and cholesterol and triglyceride levels showed a non-significant trend toward a reduction in the CNO-injected group ( Figure 7C ).
DISCUSSION
Our results show that acute, reversible chemogenetic stimulation of the rat PB results in the activation of arousal-related circuits and suppression of sleep-related circuits to produce a long-lasting continuous bout of behavioral wakefulness with a 5.0-Hz theta-rich EEG. The observed behavioral wakefulness took the form of alert but minimally active arousal, consistent with the observed 5.0-Hz theta-rich EEG, also termed ''hippocampal type 2 theta'' [24] . Surprisingly, given prevailing models of sleep homeostasis, neither an EEG nor behavioral sleep rebound was observed following the induced extended wakefulness. In fact, the NREM sleep period subsequent to CNOinduced wakefulness, which occurred at its usual time, showed a reduction, not increase, in EEG delta and theta power. The REM sleep EEG, on the other hand, was unaffected. With respect to the circuit basis by which the PB can trigger and maintain EEG and behavioral arousal, we found that selective chemogenetic activation of PB-BF-POA or PB-LH pathways induces 4 or 5 hr wakefulness, with normal wake FFT, and a subsequent sleep rebound. In sharp contrast, chemogenetic activation of the PBthalamic pathway produced only a negligible increase in waking. Repeated daily activation of the PB for 4 days similarly induced long bouts of waking behavior, although the length of the induced wake bouts became progressively shorter from days 1 to 4 (day 1-4: 11, 7, 5, and 4 hr, respectively). The 5.0-Hz theta peak observed during the induced wake was also progressively reduced following each CNO injection, returning to its nearnormal power during wake by the fourth CNO injection. The NREM sleep FFT effects after induced wakefulness, however, remained pronounced following all four daily CNO injections. Finally, despite high sleep pressure from repeated CNO-induced wake periods, no sleep rebound in sleep time or FFT change was ever observed. That these divergent effects on the sleep and wake EEG spectra are likely due to increasing sleep pressure, and not simply desensitization of the hM3Dq receptor, was strongly indicated by robust c-Fos expression in the sleep-promoting VLPO, MnPO, and PZ following the 4 th day of CNO injections. Finally, extended wakefulness taking the form of an extra $27 hr of wakefulness over 4 days resulted in significant reductions in body weight and leptin, an increase in glucose, no change in insulin, and minor, non-significant changes in cholesterol and triglycerides. Collectively, these metabolic changes are inconsistent with chronic sleep loss per se, underlying deleterious metabolic changes, at least in the rodent. In animals and humans alike, EEG and behavioral arousal depend critically upon the structural and functional integrity of the PB complex [10, 25] . With respect to the targets of the PB, i.e., the circuit basis by which the PB can trigger and maintain wake, our previous lesion study and the present study indicate that the cellular BF, a major target of the PB, exerts potent control over EEG arousal and, in a cell-type-specific manner, behavioral arousal [10, 26] . On the other hand, multiple lesion studies have shown that the thalamus, also a major target of the PB, is not critical for normal levels of wakefulness nor is selective activation of glutamatergic thalamocortical neurons sufficient to drive wakefulness [10, 26, 27] ; the results of the present study confirm and extend these prior findings concerning thalamic control of arousal. Our results, in combination with more-recent findings on the cellular BF [26, 28] , suggest that the reduced power in the lower-frequency EEG of NREM sleep and the pronounced 5-Hz theta rhythm during wakefulness following PB activation are likely driven by the PB-BF pathway, whereas behavioral wake is driven by activation of both the PB-BF-POA and PB-LH pathways, with little to no contribution from the PB-thalamus pathway. It is also of interest that the effects of PB activation on the NREM EEG persisted beyond the behavioral wake. This would suggest that EEG and behavioral wake were not completely synchronized and may link to differential activation of the ascending PB pathways. Dissociation of EEG and behavioral state has been previously described, most recently in studies showing that selective chemogenetic activation of BF cholinergic neurons produces a wake-like EEG during NREM sleep, but not behavioral wake [26, 28] .
Whereas our retrograde circuit activation studies continue to support a key role for the BF in mediating much of the PB's EEG and behavioral arousal effect, our retrograde activation and c-Fos findings suggest that the POA and LH are also important circuit elements in these processes. With respect to the POA, both the VLPO and MnPO contain sleep-active neurons [29, 30] that are inhibitory (GABA and/or galanin) and project mainly to wake-promoting neurons of the LH and posterior hypothalamus (PH) [31, 32] . The cellular LH, on the other hand, is quite heterogeneous, containing orexin, melanin-concentrating hormone (MCH), GABAergic, nitric oxide (NO), and glutamate neurons, all of which have also been implicated in wake, NREM, and/or REM sleep [33] [34] [35] [36] [37] [38] [39] [40] . The cellular PH is likewise heterogeneous, with the TMN neurons being its most notably resident population linked with arousal control. Non-selective cell body lesions of the LH that include the PH increase total sleep time by about 25% [12] . This marked increase in sleep time following LH+PH lesions is much higher than that seen following selective lesions or disruption of known LH and PH cell populations, e.g., orexin, MCH, histamine, etc. [41, 42] . Hence, another as yet unidentified population of arousal neurons in the LH and/or PH is likely operative, and findings from the present study would suggest that these putative unidentified arousal-promoting LH/ PH neurons likely receive PB inputs and may work jointly with POA neurons to regulate arousal. To this end, activation of the PB-BF-POA pathway appears to inhibit both the MnPO and VLPO, which is interesting given that the inputs from the PB are presumptively glutamatergic and thus excitatory. It may therefore be the case that inhibition of the MnPO and VLPO is mediated by PB excitation of GABAergic interneurons or direct modulation of GABAergic terminals on VLPO and MnPO sleep neurons. Indeed, the ability of the PB to robustly produce sustained wake may ultimately require simultaneous stimulation of wake-active neurons in the BF and LH/PH as well as inhibition of POA sleep neurons, ultimately reflecting multiple circuit ''layers'' of arousal control. Finally, the extent to which ''selective'' retrograde activation of the PB-LH/PH pathway may have also activated the PB-POA-BF pathway, or vice versa, remains an open question. In other words, it is possible that the retrograde-based activation of PB neurons from the LH/PH or VLPO/POA may have also resulted in the activation of the other circuit via collaterals of the PB projection neurons. We attempted to examine this possibility through mapping of c-Fos but were unable to make a definite determination one way or the other. Given, however, the results of the PB-thalamus retrograde activation, which did not produce waking, we would argue that collaterals from the primary PB projections neurons are unlikely to contribute meaningfully to the responses observed.
The extended wakefulness induced by serial PB activations produced a significant sleep debt and, hence, presumably, high sleep pressure but had opposing effects on sleep-(VLPO and PZ) and wake-regulatory neurons (TMN, LC, orexin, and BF cholinergic neurons). And this high sleep pressure-secondary to extended wakefulness-progressively reduced waking time and power in the 5.0-Hz theta band induced by CNO, i.e., PB activation. Moreover, persisting effects on the wake and NREM sleep EEG FFT were observed beyond that of behavioral waking. Hence, the effect of increasing sleep pressure on the duration of arousal is consistent with an underlying sleep homeostat, but the absence of a sleep rebound in total sleep time or increased slow-wave EEG power following PB stimulation was highly surprising. In other words, the c-Fos observed in sleepactive neurons on day 4 is consistent with high sleep pressure in the animals at this time, yet we failed to observe any EEG or behavioral sleep rebound. One possible explanation for this curious finding is that the EEG effects of PB activation persisted beyond the observed behavioral wake. Another possibility is that whereas the direct activation effect on the PB is confined to the typical 6-to 8-hr period of CNO-induced chemogenetic stimulation, the effects on target arousal circuitry may last longer than the CNO period and suppress sleep rebound.
Our results further suggest that sleep induction requires not only the activation of sleep systems but also the inactivation of key arousal circuits, whereas behavioral wakefulness only requires the activation of arousal systems. This, in turn, would suggest that the activity of the brain's arousal circuitry is the primary determinant of the level of EEG and behavioral arousal, whereas the sleep process is somewhat more permissive in nature, at least when the activity of sleep-active neurons isn't potentiated using chemogenetics or hypnotics [43] [44] [45] . From an anatomic standpoint, this has a certain intuitive appeal given that arousal systems are strongly interconnected and project widely across the neuraxis, whereas sleep systems, by and large, project more locally to nearby arousal circuits. These features suggest that these disparate populations of sleep-active neurons may not be capable of coordinating a global sleep state without arousal systems also being inactive secondary to sleep pressure, circadian regulation, or lack of inputs. From a clinical standpoint, this model of sleep-wake regulation would square well with the hypothesis that primary insomnia might reflect a state of brain hyper-arousal rather than dysfunction of sleep-promoting circuitry. Hence, drugs targeting the brain's arousal circuitry, rather than potentiating sleep circuitry, may prove more efficacious in treating primary insomnia, as has been previously hypothesized [46] .
The CNO-induced extended wakefulness in our rat model offers an experimental analog of human chronic sleep restriction, which is experienced at epidemic levels in modern society. Following 4 days of chronic sleep loss, we observed a significant reduction in body weight and leptin, an increase in blood glucose, no change in insulin, and non-significant reductions in blood cholesterol and triglyceride. These metabolic findings are generally consistent with those previously reported in rats who demonstrated chronic sleep loss but only minor, non-deleterious metabolic changes, secondary to lesions of the VLPO [18] . These prior findings, as well as those of the present study, are therefore a challenge to reconcile with human findings showing that sleep deprivation results in obesity and adverse metabolic changes [14] [15] [16] . One possible explanation for these disparate results between rodents and humans may link to the different waking metabolic rates of humans and rodents. On the other hand, there are likely factors associated with sleep deprivation or restriction in humans, including stress and hedonic drives, which may contribute to the deleterious metabolic changes seen in humans following extended wakefulness. A human model of wake extension employing repeated administration of a wake-promoting compound, such as armodafinil, could potentially minimize the stress confound inherent to the human studies and provide a better direct comparison of wake-extension/sleep-loss (as the isolated variable) between the animal and human work.
In conclusion, we show for the first time that the pontine PB can potently drive cortical arousal and wake behavior and that either the PB-POA-BF or PB-LH/PH ascending circuit pathways are sufficient to mediate, to a large degree, these responses. By contrast, the PB-thalamic pathway does not appear to contribute meaningfully to the EEG and behavioral responses produced by PB activation. We further show that repeated (daily) injections of CNO represent a novel and noninvasive model of extended wakefulness that may have great utility in elucidating the neurocognitive, physiologic, and metabolic consequences of sleep loss per se.
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